UnitedHealth stock finishes 2025 as worst performer in the Dow

UnitedHealth Group faced a challenging year in 2025, emerging as the worst-performing component in the Dow Jones Industrial Average. Its stock price plummeted by 35% during the year, trading at $327, marking a significant decline since the beginning of the year. Investors are now eagerly awaiting the upcoming earnings report scheduled for January 27, 2026, with market analysts predicting a substantial decrease in per-share profit by almost 70%. This marks the company’s toughest financial performance since the 2008 financial crisis, with a wide 52-week trading range varying from a high of $606.36 to a low of $234.60, leaving even seasoned investors unsettled.

Several factors have contributed to this decline, including a higher than expected Medical Care Ratio of 89.9%, Medicare Advantage cost increases, a leadership transition from CEO Andrew Witty to Stephen Hemsley, and ongoing investigations by the Department of Justice regarding Medicare billing practices. The turbulence in UnitedHealth’s stock performance has led to mixed sentiments among institutional investors. Major stakeholders like Wellington Management reduced their stake by 31.8%, while Capital Research Global Investors increased their position by 126.9%. Despite this volatility, institutional ownership in the company remains high at 87.86% of the equity.

Analysts are gearing up for a challenging fourth quarter of 2025, with projected adjusted earnings per share (EPS) of $2.09 compared to $6.81 in the same quarter the previous year. For the full year, adjusted profit is forecasted to decline to $16.30 per share from $27.66 in the prior year, signifying a 41% decrease. The company’s inconsistent performance in meeting profit expectations over the past four quarters adds further uncertainty to the market’s outlook.

In response to heightened scrutiny, UnitedHealth has introduced a 23-point plan to rebuild trust and address patient concerns. While regulatory pressures persist, the company’s significant scale provides some insulation. Looking ahead to 2026, a potential positive factor could be the projected rise in Medicare Advantage reimbursement rates by up to 5%, offering direct support to the core business. Management remains optimistic about seeing sustained growth in the coming year.

Analyst views on UnitedHealth present a cautiously optimistic outlook, with 15 out of 25 analysts recommending a “Strong Buy,” seven suggesting “Hold,” and one issuing a “Strong Sell” rating. The average price target stands at $394.91, indicating a potential upside of nearly 22% from current levels. With a forward price-to-earnings (P/E) ratio of around 18, solid free cash flow exceeding $17 billion, and a dividend yield of 2.7%, the company’s valuation may attract investors with a long-term investment horizon.